Browsing UiS Brage by Author "Asphaug, Lars"

Now showing items 1-2 of 2

    • Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1) 

      Ohnstad, Hege Oma; Blix, Egil Støre; Akslen, Lars Andreas; Gilje, Bjørnar; Raj, Sunil Xavier; Skjerven, Helle; Borgen, Elin; Janssen, Emiel; Mortensen, Elin Synnøve; Brekke, Marianne B.; Falk, Ragnhild Sørum; Schlichting, Ellen; Boge, Beate; Songe-Møller, Silje; Olsson, Pernilla Marie A.; Heie, Anette; Mannsåker, Bård; Vestlid, Magdalena Aas; Kursetgjerde, Torgunn; Gravdehaug, Berit; Suhrke, Pål; Sánchez, E.; Bublevic, J.; Røe, Oluf Dimitri; Geitvik, Gry; Halset, Eline Holli; Rypdal, Maria Christine; Langerød, Anita; Lømo, Jon; Garred, Øystein; Porojnicu, Alina Carmen; Engebraaten, O.; Geisler, Jürgen; Lyngra, Marianne; Hansen, M. H.; Søiland, Håvard; Nakken, T.; Asphaug, Lars; Kristensen, Vessela N.; Sørlie, Therese; Sørlie, T.; Nygård, Jan Franz; Kiserud, Cecilie E.; Reinertsen, Kristin Valborg; Russnes, Hege Elisabeth Giercksky; Naume, Bjørn (Peer reviewed; Journal article, 2024)
      Background EMIT-1 is a national, observational, single-arm trial designed to assess the value of the Prosigna, Prediction Analysis of Microarray using the 50 gene classifier (PAM50)/Risk of Recurrence (ROR), test as a ...

    • Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P) 

      Löffeler, Sven; Bertilsson, Helena Maria; Müller, Christoph Rainer; Aas, Kirsti; Haugnes, Hege Sagstuen; Aksnessæther, Bjørg Yksnøy; Pesonen, Maiju; Thon, Kristian; Tandstad, Torgrim; Murtola, Teemu; Poulsen, Mads Hvid Aaberg; Nordstrøm, Tobias; Vigmostad, Maria Nyre; Ottosson, Fredrik; Holmsten, Karin; Christiansen, Ola B.; Slaaen, Marit; Haug, Erik Skaaheim; Storås, Anne Holck; Asphaug, Lars; Rannikko, Antti; Brasso, Klaus (Peer reviewed; Journal article, 2024-03)
      Background Older men (aged ≥75 years) with high risk, non-metastatic prostate cancer (PCa) are increasingly treated with curative therapy (surgery or radiotherapy). However, it is unclear if curative therapy prolongs life ...